EP0823941A4 - Human antibodies derived from immunized xenomice - Google Patents

Human antibodies derived from immunized xenomice

Info

Publication number
EP0823941A4
EP0823941A4 EP95918935A EP95918935A EP0823941A4 EP 0823941 A4 EP0823941 A4 EP 0823941A4 EP 95918935 A EP95918935 A EP 95918935A EP 95918935 A EP95918935 A EP 95918935A EP 0823941 A4 EP0823941 A4 EP 0823941A4
Authority
EP
European Patent Office
Prior art keywords
human antibodies
antibodies derived
immunized xenomice
xenomice
immunized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95918935A
Other languages
German (de)
French (fr)
Other versions
EP0823941A1 (en
Inventor
Raju Kucherlapati
Aya Jakobovits
Sue Klapholz
Daniel G Brenner
Daniel J Capon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenix Inc filed Critical Abgenix Inc
Publication of EP0823941A1 publication Critical patent/EP0823941A1/en
Publication of EP0823941A4 publication Critical patent/EP0823941A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP95918935A 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice Withdrawn EP0823941A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/005500 WO1996034096A1 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice
CA002219486A CA2219486A1 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice

Publications (2)

Publication Number Publication Date
EP0823941A1 EP0823941A1 (en) 1998-02-18
EP0823941A4 true EP0823941A4 (en) 2001-09-19

Family

ID=25679770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95918935A Withdrawn EP0823941A4 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice

Country Status (4)

Country Link
EP (1) EP0823941A4 (en)
AU (1) AU2466895A (en)
CA (1) CA2219486A1 (en)
WO (1) WO1996034096A1 (en)

Families Citing this family (1463)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5795966A (en) † 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
EP1854481B1 (en) 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
EP0859633A2 (en) * 1996-08-16 1998-08-26 Kurt B. Osther Method for treating diabetes
AU2008200005B2 (en) * 1996-12-03 2012-05-17 Amgen Fremont Inc. Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
JPH10324639A (en) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Preventing and therapeutic agent for disease associated with sensitized t cell containing il-6 antagonist as active ingredient
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2296322A1 (en) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
EP1895002B1 (en) 1998-11-04 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Novel trypsin family serine proteases
US6410824B1 (en) 1998-12-09 2002-06-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
ES2340745T3 (en) 1998-12-23 2010-06-08 Pfizer Inc. HUMAN MONOCLONAL ANTIBODIES AGAINST CTLA-4.
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU3674000A (en) 1999-04-09 2000-11-14 Chugai Research Institute For Molecular Medicine, Inc. Novel fetal genes
PL200134B1 (en) 1999-05-07 2008-12-31 Genentech Inc Treatment of autoimmunologic diseases with antagonists binding to cell surface markers
ES2557768T3 (en) 1999-06-01 2016-01-28 Biogen Ma Inc. A blocking monoclonal antibody against VLA-1 and its use for the treatment of inflammatory disorders
DK1188830T3 (en) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd New hemopoietin receptor protein NR10
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2277846T3 (en) * 1999-07-29 2007-08-01 Medarex, Inc. HUMAN MONOCLONAL ANTIBODIES FOR SPECIFIC PROSTATIC ANTIGEN.
WO2001013940A1 (en) 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Hm1.24 antigen expression potentiators
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU6871900A (en) 1999-09-06 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Tsg-like gene
DE60042220D1 (en) 1999-09-21 2009-06-25 Chugai Pharmaceutical Co Ltd USE OF TRANSPORTATION OATP-C TO SCREENING TEST SUBSTANCES
EP2351483A1 (en) 1999-10-01 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of blood coagulation-related diseases
CA2397904A1 (en) 2000-01-24 2001-07-26 Haruo Sugiyama Wt1 interacting protein wtip
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US6653448B1 (en) 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
ES2614260T3 (en) 2000-05-26 2017-05-30 Immunex Corporation Use of antibodies against the interleukin-4 receptor and compositions thereof
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
KR20080074231A (en) 2000-06-29 2008-08-12 아보트 러보러터리즈 Dual specificity antibodies and methods of making and using
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE60143535D1 (en) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic HUMAN ANTIBODIES AGAINST CD40
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
JP4434580B2 (en) 2000-11-28 2010-03-17 メディミューン，エルエルシー Methods for administering / prescribing anti-RSV antibodies for prevention and treatment
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
HUP0302525A2 (en) 2001-01-05 2003-10-28 Abgenix, Inc. Antibodies to insulin-like growth factor i receptor
EP1373318A2 (en) * 2001-01-26 2004-01-02 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
JP2005503116A (en) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Human G protein chemokine receptor (CCR5) HDGNR10
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP2005508608A (en) 2001-03-22 2005-04-07 アボット ゲーエムベーハー ウント カンパニー カーゲー Transgenic animals expressing antibodies specific to the gene of interest and uses thereof
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
JP2005519580A (en) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Human anti-pneumococcal antibody derived from non-human animals
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
AU2002332628B2 (en) 2001-08-23 2007-07-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
DK2319301T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR101080021B1 (en) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 Antibody-containing solution pharmaceuticals
ATE435239T1 (en) 2002-03-29 2009-07-15 Schering Corp HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
WO2003083116A1 (en) 2002-03-29 2003-10-09 Chugai Seiyaku Kabushiki Kaisha Emthod of screening transporter inhibitor
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
CA2429483A1 (en) 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
EP1513934B1 (en) 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
CN101613405A (en) 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 Gene relevant and polypeptide with human colon carcinoma
EP1531848A4 (en) 2002-06-10 2007-03-28 Vaccinex Inc Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004007682A2 (en) 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Method of stabilizing protein solution preparation
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
ES2626268T3 (en) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Protein Purification Method
TW200418988A (en) 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1795595A1 (en) 2002-10-22 2007-06-13 Eisai R&D Management Co., Ltd. Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
AU2003280643A1 (en) 2002-10-30 2004-05-25 Chugai Seiyaku Kabushiki Kaisha Membrane protein originating in mast cells
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2003291002A1 (en) 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
ES2347239T3 (en) 2002-12-02 2010-10-27 Amgen Fremont Inc. ANTIBODIES DIRECTED TO THE TUMOR NECROSIS FACTOR AND USES OF THE SAME.
AU2003242352A1 (en) 2002-12-29 2004-07-29 Center For Advanced Science And Technology Incubation, Ltd. Adiponectin receptor and gene coding for the same
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
RS54160B1 (en) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Nogo receptor binding protein
KR20120035234A (en) 2003-04-11 2012-04-13 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
AU2004231094A1 (en) * 2003-04-14 2004-10-28 Board Of Regents, The University Of Texas System Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
DE602004028249D1 (en) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd FUCOSETRANSPORTER
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc Osteoarthritis biomarkers and uses thereof
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
US8029984B2 (en) 2003-08-08 2011-10-04 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis and therapy
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (en) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
ES2484340T3 (en) 2003-12-05 2014-08-11 Multimmune Gmbh Therapeutic and diagnostic anti hsp70 antibodies
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
PT2311873T (en) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc M-csf-specific monoclonal antibody and uses thereof
DK2177537T3 (en) 2004-01-09 2011-12-12 Pfizer Antibodies to MAdCAM
MXPA06009072A (en) 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
US7700573B2 (en) 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
WO2005116657A2 (en) 2004-05-24 2005-12-08 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
ES2694123T3 (en) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Swine influenza virus modified by genetic engineering and uses thereof
KR20120133403A (en) 2004-06-01 2012-12-10 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
CA2572193A1 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving oligodendrocytes with sp35 based agents
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
CN101027390B (en) 2004-07-22 2012-12-12 卫材R&D管理有限公司 Lrp4/Corin dopamine-producing neuron precursor cell marker
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
EP1791568B1 (en) 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
CA2958259C (en) 2004-10-22 2020-06-30 Revivicor, Inc. Ungulates with genetically modified immune systems
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
EP1827491A4 (en) 2004-11-19 2010-07-14 Biogen Idec Inc Treatment for multiple sclerosis
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5185624B2 (en) 2004-12-02 2013-04-17 ドマンティス リミテッド Bispecific antibodies targeting serum albumin and GLP-1 or PYY
JP4881874B2 (en) 2004-12-06 2012-02-22 協和発酵キリン株式会社 Human monoclonal antibody against influenza M2 protein, production method thereof and use thereof
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
JPWO2006067847A1 (en) 2004-12-22 2008-06-12 中外製薬株式会社 Antibody production method using cells in which fucose transporter function is inhibited
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CN101495498B (en) 2005-02-07 2013-09-18 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
BRPI0608210A2 (en) 2005-02-14 2010-11-09 Wyeth Corp methods of diagnosing an il-17f-related disorder in an individual and selecting compounds capable of inhibiting il-17f binding in il-17r, use of an il-17f antagonist, pharmaceutical composition, and vaccine adjuvant
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc Treating neurological disorders
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
TWI406870B (en) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
PT1850874E (en) 2005-02-23 2013-12-02 Genentech Inc Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
KR101213894B1 (en) 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Kim-1 antibodies for treatment of th2-mediated conditions
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
ES2720288T3 (en) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferation of cells expressing MUC1
ES2440953T3 (en) 2005-03-31 2014-01-31 The General Hospital Corporation Modulation of HGF / HGFR activity to treat lymphedema
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PL2645106T3 (en) 2005-04-04 2017-11-30 Biogen Ma Inc. Methods for evaluating an immune response to a therapeutic agent
CA2957144C (en) 2005-04-08 2020-06-02 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
GT200600148A (en) 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2605964A1 (en) 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
MX2007013217A (en) 2005-04-25 2008-03-11 Pfizer Antibodies to myostatin.
AP2552A (en) 2005-04-26 2013-01-08 Pfizer P-cadherin antibodies
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
MX2007014474A (en) 2005-05-17 2008-02-07 Univ Connecticut Compositions and methods for immunomodulation in an organism.
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
EA018255B1 (en) 2005-05-27 2013-06-28 Байоджен Айдек Ма Инк. Tweak binding proteins and use thereof
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101243105A (en) * 2005-06-22 2008-08-13 健泰科生物技术公司 Methods and compositions for targeting IFNAR2
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
TR201902033T4 (en) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and uses.
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
EP2336780A1 (en) 2005-07-27 2011-06-22 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
NZ566520A (en) 2005-08-18 2012-03-30 Genmab As Therapy with CD4 binding peptides and radiation
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN103450359B (en) 2005-08-19 2018-07-24 惠氏有限责任公司 The antagonist antibodies of anti-GDF-8 and the purposes in ALS and other GDF-8- associated disorder treatments
PL2960253T3 (en) 2005-09-07 2018-11-30 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
ES2527961T3 (en) 2005-09-26 2015-02-02 Medarex, L.L.C. Human monoclonal antibodies to CD70
WO2007039256A2 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
JP5191235B2 (en) 2005-10-21 2013-05-08 中外製薬株式会社 Heart disease treatment
KR20180002911A (en) 2005-11-04 2018-01-08 제넨테크, 인크. Use of complement pathway inhibitors to treat ocular diseases
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2007055378A1 (en) 2005-11-14 2007-05-18 Cell Signals Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
AR057941A1 (en) 2005-11-25 2007-12-26 Univ Keio THERAPEUTIC AGENTS FOR PROSTATE CANCER
EP2567973B1 (en) 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN101506236B (en) 2005-11-30 2012-12-12 雅培制药有限公司 Monoclonal antibodies against amyloid beta protein and uses thereof
CA2632094C (en) 2005-12-02 2015-01-27 Wayne A. Marasco Carbonic anhydrase ix (g250) antibodies and methods of use thereof
JP2009518314A (en) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling comprising antibodies that bind IL-22 and antibodies that bind IL-22R
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
PL2251034T3 (en) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc Ctla-4 antibody dosage escalation regimens
JP5302007B2 (en) 2005-12-13 2013-10-02 アストラゼネカ アクチボラグ Binding protein specific for insulin-like growth factor and use thereof
ES2535856T3 (en) 2005-12-15 2015-05-18 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
EP1981538B1 (en) 2005-12-30 2014-09-17 Dyax Corporation Metalloproteinase binding proteins
WO2007084321A2 (en) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
ES2396440T3 (en) 2006-01-18 2013-02-21 The General Hospital Corporation Methods of increasing lymphatic function
UY30097A1 (en) 2006-01-20 2007-08-31 Atugen Ag THERAPEUTIC USES OF RTP801 INHIBITORS
WO2007096779A2 (en) 2006-01-25 2007-08-30 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
AR059213A1 (en) 2006-01-27 2008-03-19 Univ Keio THERAPEUTIC AGENTS FOR DISEASES INVOLVING COROIDAL NEOVASCULARIZATION
US8669345B2 (en) 2006-01-27 2014-03-11 Biogen Idec Ma Inc. Nogo receptor antagonists
US7803561B2 (en) 2006-02-06 2010-09-28 Rhode Island Hospital GPR30 estrogen receptor in breast cancers
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP2311478B1 (en) 2006-03-20 2014-07-16 Japan Science and Technology Agency Use of ip3 receptor-binding protein for controlling intracellular pH
JP2009529915A (en) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド Human antibodies and methods specific for gastrin substances
CA2645853A1 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
JP5514539B2 (en) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
KR20090029184A (en) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Antibody compositions and methods for treatment of neoplastic disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP5242382B2 (en) 2006-04-14 2013-07-24 株式会社医学生物学研究所 Polypeptide variant having effector function
PL2034830T3 (en) 2006-05-25 2015-04-30 Biogen Ma Inc Anti-vla-1 antibody for treating stroke
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
ES2429407T3 (en) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Preventive agent or remedy for inflammatory diseases
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
MX2009000487A (en) 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Cell death inducer.
KR101528939B1 (en) 2006-07-18 2015-06-15 사노피 Antagonist antibody against epha2 for the treatment of cancer
JP5175729B2 (en) 2006-07-21 2013-04-03 中外製薬株式会社 Kidney disease treatment
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
MX2009001293A (en) 2006-08-03 2009-02-11 Astrazeneca Ab Antibodies directed to â¿vãy6 and uses thereof.
AU2007281774A1 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to ErbB 2
KR101437188B1 (en) 2006-08-04 2014-10-02 노바르티스 아게 Ephb3-specific antibody and uses thereof
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
ME00588A (en) 2006-08-18 2011-12-20 Prlr-specific antibody and uses thereof
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
UA115964C2 (en) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані INTERLAYKIN-13-Binding Protein
CA2662236A1 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antibody having enhanced adcc activity and method for production thereof
WO2008060776A2 (en) 2006-10-03 2008-05-22 University Of Medicine And Dentistry Of New Jersey Atap peptides, nucleic acids encoding the same and associated methods of use
NZ576855A (en) 2006-10-12 2012-08-31 Forerunner Pharma Res Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
KR20090069330A (en) 2006-10-12 2009-06-30 와이어쓰 Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101589059A (en) 2006-10-20 2009-11-25 株式会社未来创药研究所 Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MX2009004519A (en) 2006-11-03 2009-05-12 Wyeth Corp Glycolysis-inhibiting substances in cell culture.
JP5570218B2 (en) 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング FGFR4 antibody
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
ES2476798T3 (en) 2006-11-27 2014-07-15 Patrys Limited New glycosylated peptide target in neoplastic cells
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101678100A (en) 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
CL2007003661A1 (en) 2006-12-18 2008-07-18 Genentech Inc VARIABLE AND LIGHT VARIABLE HEAVY CHAIN REGIONS; NUCLEIC ACIDS THAT CODE THEM; METHOD OF PRODUCTION; ANTI-NOTCH3 ANTIBODIES THAT UNDERSTAND THEM; AND USE OF ANTIBODIES TO TREAT DISEASES RELATED TO THE RECEIVER NOTCH3.
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
CN103408661B (en) 2007-01-05 2016-04-06 苏黎世大学 The method of disease-specific binding molecules and target is provided
AU2008205244B2 (en) 2007-01-09 2013-02-07 Biogen Ma Inc. Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
MX2009007830A (en) 2007-01-23 2009-10-07 Univ Shinshu Chronic rejection inhibitor.
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
US8609405B2 (en) 2007-02-09 2013-12-17 Eisai R&D Management Co., Ltd. GABA neuron progenitor cell marker 65B13
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CN101951953A (en) 2007-02-27 2011-01-19 株式会社未来创药研究所 Contain the pharmaceutical composition of anti-GRP78 antibody as effective ingredient
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
US8519106B2 (en) 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
SI2125894T1 (en) 2007-03-22 2019-05-31 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc Antibodies with decreased deamidation profiles
PE20081899A1 (en) 2007-04-02 2009-01-26 Pfizer ANTI-IGE ANTIBODIES
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
WO2008144761A2 (en) 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2008157356A2 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
JP5718637B2 (en) 2007-06-21 2015-05-13 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and its use
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009014263A1 (en) 2007-07-26 2009-01-29 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
MX2010002018A (en) 2007-08-20 2010-05-27 Oncotherapy Science Inc Cdh3 peptide and medicinal agent comprising the same.
SG183698A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same
KR101543624B1 (en) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 FOXM peptide and medicinal agent comprising the same
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
SI2195023T1 (en) 2007-08-29 2018-07-31 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
KR20100080519A (en) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 Compositions and methods of using proislet peptides and analogs thereof
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
PT2207809E (en) 2007-09-26 2013-10-09 Amgen Inc Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
BRPI0817637A2 (en) 2007-09-28 2015-09-08 Chugai Pharmaceutical Co Ltd anti-glipican-3 antibody having improved plasma kinetics
CA2701155C (en) 2007-10-02 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN101802192A (en) 2007-10-15 2010-08-11 中外制药株式会社 Method for production of antibody
CN101965365A (en) 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 Antibody capable of combining the soluble ass oligomer specifically and application thereof
JP5620106B2 (en) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 Polypeptide having enhanced effector function
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
CN101910414B (en) 2007-11-07 2016-01-13 健泰科生物技术公司 For assessment of the method and composition of the responsiveness of B cell lymphoma antagonism CD40 Antybody therapy
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
EP2918605A1 (en) 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
CN101918452A (en) 2007-11-15 2010-12-15 中外制药株式会社 Monoclonal antibody capable of binding to Anexelekto, and use thereof
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc Protein formulation
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
RU2531521C2 (en) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Nr10 antibody and using it
MX2010006097A (en) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus.
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
WO2009075344A1 (en) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
CN101952315B (en) 2007-12-26 2015-04-01 生物测试股份公司 Agents targeting CD138 and uses thereof
DK2242772T3 (en) 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
CA2710483C (en) 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
JP5608100B2 (en) 2008-02-08 2014-10-15 メディミューン，エルエルシー Anti-IFNAR1 antibodies with reduced Fc ligand affinity
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RU2497545C2 (en) 2008-03-18 2013-11-10 Эбботт Лэборетриз Method of treating psoriasis (versions)
EP2260102A1 (en) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
AU2009231733B2 (en) 2008-03-31 2015-12-24 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI547287B (en) 2008-04-25 2016-09-01 戴埃克斯有限公司 Fc receptor binding proteins
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2282773B1 (en) 2008-05-02 2014-01-15 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101649189B1 (en) 2008-05-09 2016-08-18 애브비 인코포레이티드 Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt antibodies
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102256623A (en) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 Neuroinvasion inhibitor
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
RU2559525C2 (en) 2008-07-08 2015-08-10 Эббви Инк Proteins binding prostaglandin e2 and using them
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
ES2442024T3 (en) 2008-07-15 2014-02-07 Academia Sinica Glucan matrices on glass slides coated with PTFE type aluminum and related methods
NZ590816A (en) 2008-08-14 2013-02-22 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
CN102239180B (en) 2008-08-18 2014-12-31 辉瑞大药厂 Antibodies to CCR2
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
JP5796831B2 (en) 2008-09-03 2015-10-21 ジェネンテック， インコーポレイテッド Multispecific antibody
MX2011002478A (en) 2008-09-07 2011-04-05 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use.
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
JP2012504939A (en) 2008-09-23 2012-03-01 ワイス・エルエルシー Method for predicting the generation of activation signals by cross-linked proteins
KR101987351B1 (en) 2008-09-30 2019-06-10 아블렉시스, 엘엘씨 Non-human mammals for the production of chimeric antibodies
KR20140101876A (en) 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 Method for inducing pluripotency in cells
JP2012505900A (en) 2008-10-14 2012-03-08 ダイアクス コーポレーション Use of an IGF-II / IGF-IIE binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma
EP2352521B1 (en) 2008-10-14 2020-09-16 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2350270B1 (en) 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Human ebola virus species and compositions and methods thereof
EP2348827B1 (en) 2008-10-27 2015-07-01 Revivicor, Inc. Immunocompromised ungulates
CN102271707B (en) 2008-10-29 2015-04-08 阿布林克斯公司 Formulations of single domain antigen binding molecules
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
PL2949666T3 (en) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Human anti-alpha-synuclein antibodies
CN106432503B (en) 2008-12-19 2020-03-06 宏观基因有限公司 Covalent diabodies and uses thereof
WO2010073972A1 (en) 2008-12-22 2010-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for obtaining pancreatic progenitor cell using neph3
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI0918204A2 (en) 2008-12-23 2015-12-08 Genentech Inc igv variant pharmaceutical composition and kit
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
MX2011006908A (en) 2008-12-26 2011-10-06 Univ Tokio Diagnosis and treatment of cancer using anti-lgr7 antibody.
CN102341411A (en) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 Anti-lymphotoxin antibodies
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (en) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 Antibody mediated osseous regeneration
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8309530B2 (en) 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
EP2411412B1 (en) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against light and uses thereof
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
KR101766927B1 (en) 2009-04-01 2017-08-09 제넨테크, 인크. Treatment of insulin-resistant disorders
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
ES2571235T3 (en) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
RU2595379C2 (en) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. ANTIBODIES AGAINST TNF-α AND USE THEREOF
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
MX2011010938A (en) 2009-04-18 2012-01-12 Genentech Inc Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies.
CA2764432C (en) 2009-04-27 2017-10-24 Kyowa Hakko Kirin Co., Ltd. Interleukin-3 receptor alpha chain-binding antibody to treat leukemia
ES2725356T3 (en) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc ERG2 monoclonal antibodies and their therapeutic use
CN102753579A (en) 2009-05-01 2012-10-24 国立大学法人东京大学 Anti-cadherin antibody
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
WO2010138564A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Of New York University Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5808052B2 (en) 2009-05-29 2015-11-10 中外製薬株式会社 Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2443150B1 (en) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011003996A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
WO2011006001A1 (en) 2009-07-09 2011-01-13 Genentech, Inc. Animal model for the evaluation of adjuvant therapies of cancer
MX2012000620A (en) 2009-07-13 2012-01-27 Genentech Inc Diagnostic methods and compositions for treatment of cancer.
AR077595A1 (en) 2009-07-27 2011-09-07 Genentech Inc COMBINATION TREATMENTS
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
NZ598127A (en) 2009-07-31 2014-03-28 Shin Maeda Cancer metastasis inhibitor
RU2567803C2 (en) 2009-07-31 2015-11-10 Дженентек, Инк. INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS
EP2462451B1 (en) 2009-08-05 2016-02-17 Nexigen GmbH Human hcv-interacting proteins and methods of use
WO2011016239A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
KR20120059553A (en) 2009-08-14 2012-06-08 제넨테크, 인크. Biological markers for monitoring patient response to vegf antagonists
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
CN102574917A (en) 2009-08-17 2012-07-11 株式会社未来创药研究所 Pharmaceutical composition containing anti-HB-EGF antibody as active ingredient
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
TWI465250B (en) 2009-08-29 2014-12-21 Abbvie Inc Therapeutic dll4 binding proteins
IN2012DN02737A (en) 2009-09-01 2015-09-11 Abbott Lab
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
IN2012DN02485A (en) 2009-09-03 2015-08-28 Hoffmann La Roche
CN102597776A (en) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 Method to identify a patient with an increased likelihood of re sponding to an anti-cancer agent
SG179135A1 (en) 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
US20110064732A1 (en) 2009-09-17 2011-03-17 Sanne Lysbet De Haas Methods and compositions for diagnostic use in cancer patients
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
WO2011041336A2 (en) 2009-09-30 2011-04-07 Genentech, Inc. Methods of treating cancer using notch antagonists
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
KR101953075B1 (en) 2009-10-07 2019-02-27 제넨테크, 인크. Methods for treating, diagnosing, and monitoring lupus
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
KR20140015139A (en) 2009-10-15 2014-02-06 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
HUE033492T2 (en) 2009-10-26 2017-12-28 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
CN102753580A (en) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 Anti-egfr antibodies and their uses
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
EP2719708B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
KR101573109B1 (en) 2009-11-24 2015-12-01 메디뮨 리미티드 Targeted binding agents against b7-h1
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN102656190A (en) 2009-12-08 2012-09-05 雅培股份有限两合公司 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
ES2565208T3 (en) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anti-VEGF-C antibodies and methods of use thereof
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
CN107095846A (en) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 Antibody formulations
MX2012007379A (en) 2009-12-23 2012-08-31 Genentech Inc Anti-bv8 antibodies and uses thereof.
RS57870B1 (en) 2010-01-06 2018-12-31 Dyax Corp Plasma kallikrein binding proteins
EP2523976B1 (en) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES
WO2011092989A1 (en) 2010-01-29 2011-08-04 東レ株式会社 Polylactic acid-based resin sheet
SG183272A1 (en) 2010-02-10 2012-09-27 Fujifilm Ri Pharma Co Ltd Radioactive metal-labeled anti-cadherin antibody
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102985441B (en) 2010-02-19 2015-04-22 俄克拉何马大学董事会 Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc Therapeutic dll4 binding proteins
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
CA2792537A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
EP2553100B1 (en) 2010-03-31 2017-07-05 Ablexis, LLC Genetic engineering of non-human animals for the production of chimeric antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
NZ623807A (en) 2010-04-13 2016-03-31 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
PT3202789T (en) 2010-04-16 2020-06-16 Biogen Ma Inc Anti-vla-4 antibodies
US20130034543A1 (en) 2010-04-19 2013-02-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Modulating xrn1
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
CN104777301B (en) 2010-05-10 2018-04-20 中央研究院 The measure of the Oseltamivir neurological susceptibility of zanamivir phosphonate ester congener and influenza virus with anti-influenza activity
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
DK2578231T3 (en) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd ANTI-TUMOR T-CELL RESPONSE AMPLIFIER
JP5904552B2 (en) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター Pancreatic cancer treatment
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2575882B1 (en) 2010-06-02 2017-11-01 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
KR20130098165A (en) 2010-06-03 2013-09-04 제넨테크, 인크. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
KR101834026B1 (en) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 Anti-gd2 antibodies
KR20130036276A (en) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Antibodies to the c3d fragment of complement component 3
ES2706913T3 (en) 2010-06-25 2019-04-01 Univ Aston Glycoproteins that have lipid mobilization properties and therapeutic uses thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CA2805572A1 (en) 2010-07-16 2012-01-19 Martin Hegen Modified single domain antigen binding molecules and uses thereof
WO2012010551A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130126576A (en) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
AU2011283669A1 (en) 2010-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Chimeric IL-1 receptor type I agonists and antagonists
JP5964300B2 (en) 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and its use
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
RS63063B1 (en) 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antibodies and their use
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012025636A1 (en) 2010-08-27 2012-03-01 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
EP2614080A1 (en) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same
SI2627672T1 (en) 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Human anti-tau antibodies
ES2730941T7 (en) 2010-10-22 2020-05-27 Seattle Genetics Inc Synergistic effects between auristatin-based antibody-drug conjugate conjugates and PI3K-AKT-mTOR pathway inhibitors
CA2816021A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US9328160B2 (en) 2010-10-29 2016-05-03 Perseus Proteomics Inc. Anti-CDH3 antibody having high internalization capacity
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112013013311A2 (en) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd cytotoxicity-inducing therapeutic agent
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
CN103380145B (en) 2010-12-17 2016-10-12 生物控股有限公司 The mankind's anti-SOD1 antibody
CA2822610C (en) 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Use of anti-p-selectin antibodies
RU2627171C2 (en) 2010-12-21 2017-08-03 Эббви Инк. Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application
TW201307388A (en) 2010-12-21 2013-02-16 Abbott Lab IL-1 binding proteins
WO2012083370A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
AU2011352207B2 (en) 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
KR102147548B1 (en) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
JP6271254B2 (en) 2011-02-28 2018-01-31 ジェネンテック， インコーポレイテッド Methods for predicting biological markers and responses to B cell antagonists
PL3235508T3 (en) 2011-03-16 2021-07-12 Sanofi Compositions comprising a dual v region antibody-like protein
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
US20140010756A1 (en) 2011-03-18 2014-01-09 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
JP6130350B2 (en) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． Methods of treating immune disorders with single domain antibodies against TNFα
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
AU2012240231B2 (en) 2011-04-04 2017-05-25 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
JP6145088B2 (en) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド Deimmunized serum binding domain and its use to extend serum half-life
CN103857699B (en) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 Multivalence and unit price polyspecific complex and application thereof
AR086543A1 (en) 2011-05-25 2014-01-08 Bg Medicine Inc GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
BR112013030352B1 (en) 2011-06-02 2020-05-19 Dyax Corp isolated anti-fcrn antibody, pharmaceutical composition comprising said antibody, isolated nucleic acid, vector, cell and therapeutic use of said antibody
KR102051014B1 (en) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Antibodies specific for tgf-beta
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
EP2718327A1 (en) 2011-06-06 2014-04-16 Neotope Biosciences Limited Mcam antagonists and methods of treatment
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
SI2723379T1 (en) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
TWI687441B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
JP2013040160A (en) 2011-07-01 2013-02-28 Genentech Inc Use of anti-cd83 agonist antibody for treating autoimmune disease
DE202011103324U1 (en) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutic anti-TIRC7 antibodies for use in immune and other diseases
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
JP6176849B2 (en) 2011-07-19 2017-08-09 中外製薬株式会社 A stable protein-containing preparation containing arginine amide or a similar compound
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
CN103890008A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Inhibition of angiogenesis in refractory tumors
WO2013027802A1 (en) 2011-08-23 2013-02-28 中外製薬株式会社 Novel anti-ddr1 antibody having anti-tumor activity
US9447192B2 (en) 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2012310880B2 (en) 2011-09-21 2015-12-03 Fujirebio Inc. Antibody against affinity complex
JP2014533929A (en) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Bispecific binding molecules for 5T4 and CD3
KR102366029B1 (en) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule inducing immune response to target antigen
CA3186007A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
TWI827333B (en) 2011-09-30 2023-12-21 日商中外製藥股份有限公司 Antigen-binding molecules that promote antigen disappearance
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
WO2013050540A1 (en) 2011-10-05 2013-04-11 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
MX2014004074A (en) 2011-10-05 2014-06-05 Genentech Inc Methods of treating liver conditions using notch2 antagonists.
JP6466170B2 (en) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション Medium for stem cell growth and induction
EP2768851B1 (en) 2011-10-21 2017-05-31 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
RU2014120981A (en) 2011-10-24 2015-12-10 Эббви Инк. IMMUNE BINDING AGENTS AGAINST SCLEROSTINE
KR20140084253A (en) 2011-10-24 2014-07-04 애브비 인코포레이티드 Immunobinders directed against tnf
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
CN108704132A (en) 2011-10-31 2018-10-26 弗·哈夫曼-拉罗切有限公司 Antibody preparation
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN104271599A (en) 2011-11-08 2015-01-07 辉瑞公司 Methods of treating inflammatory disorders using anti-M-CSF antibodies
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
CA2855746A1 (en) 2011-11-16 2013-05-23 John Stephen HILL Methods of treating epidermal growth factor deletion mutant viii related disorders
LT2785375T (en) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
RU2632108C2 (en) 2011-12-08 2017-10-02 Биотест Аг Applications of immunoconjugates, the target of which is cd138
US9636398B2 (en) 2011-12-14 2017-05-02 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791173B1 (en) 2011-12-14 2020-07-29 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2013098419A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
AU2013208003B2 (en) 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN104411717A (en) 2012-01-09 2015-03-11 斯克利普斯研究所 Humanized antibodies with ultralong CDR3S
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
KR20140114415A (en) 2012-01-13 2014-09-26 제넨테크, 인크. Biological markers for identifying patients for treatment with vegf antagonists
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MX2014009043A (en) 2012-01-31 2014-10-14 Genentech Inc Anti-ig-e m1' antibodies and methods using same.
EA034778B1 (en) 2012-02-06 2020-03-19 Инхибркс, Инк. Cd47 antibodies and methods of use thereof
CN113480639A (en) 2012-02-09 2021-10-08 中外制药株式会社 Fc region variants of antibodies
CN108324943B (en) 2012-02-10 2024-03-08 思进股份有限公司 Detection and treatment of CD30+ cancers
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (en) 2012-02-15 2017-11-02 Novo Nordisk A/S Antibodies that bind to and block a trigger receptor expressed in myeloid cells 1 (TREM-1)
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
KR102219987B1 (en) 2012-02-24 2021-02-25 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
CA2864177C (en) 2012-03-01 2019-11-26 Amgen Research (Munich) Gmbh Prolonged half-life albumin-binding protein fused bispecific antibodies
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RS59076B1 (en) * 2012-03-16 2019-09-30 Regeneron Pharma Rodents expressing ph-sensitive immunoglobulin sequences
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
LT2825036T (en) 2012-03-16 2018-07-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
CN107099581B (en) 2012-03-27 2021-07-13 弗·哈夫曼-拉罗切有限公司 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5 antibody and utilization thereof
AU2013237929B2 (en) 2012-03-29 2017-09-14 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
BR112014024219A8 (en) 2012-03-30 2017-07-25 Genentech Inc METHODS FOR DETERMINING, OPTIMIZING THERAPEUTIC EFFECTIVENESS, MONITORING, THERAPY SELECTION AND DISORDER DIAGNOSIS AND KIT
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center Tiki inhibitors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
JP6411329B2 (en) 2012-05-04 2018-10-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Affinity matured anti-CCR4 humanized monoclonal antibody and methods of use
JP2015518829A (en) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-2 antagonist for treatment of conditions involving motor neurons
MX349035B (en) 2012-05-17 2017-07-07 Extend Biosciences Inc Carriers for improved drug delivery.
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
JPWO2013180200A1 (en) 2012-05-30 2016-01-21 中外製薬株式会社 Target tissue specific antigen binding molecule
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
JP6628966B2 (en) 2012-06-14 2020-01-15 中外製薬株式会社 Antigen binding molecule containing an altered Fc region
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
CN104661677A (en) 2012-06-22 2015-05-27 西托姆克斯治疗公司 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
UY34905A (en) 2012-07-12 2014-01-31 Abbvie Inc IL-1 UNION PROTEINS
US9765156B2 (en) 2012-07-13 2017-09-19 The Trustees Of The University Of Pennsylvania Enhancing activity of CAR T cells by co-introducing a bispecific antibody
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2888238A4 (en) 2012-08-21 2016-01-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
TWI697501B (en) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 FcγRIIIb-specific Fc region variants
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found Target peptides for immunotherapy and diagnostics
KR102617499B1 (en) 2012-08-31 2023-12-22 이뮤노젠 아이엔씨 Diagnostic assays and kits for detection of folate receptor 1
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (en) 2012-09-02 2015-04-22 애브비 인코포레이티드 Methods to control protein heterogeneity
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
TWI595007B (en) 2012-09-10 2017-08-11 Neotope Biosciences Ltd Anti-mcam antibodies and associated methods of use
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
JP6117222B2 (en) 2012-09-27 2017-04-19 中外製薬株式会社 FGFR3 fusion gene and drug targeting the same
MX358997B (en) 2012-09-28 2018-09-12 Chugai Pharmaceutical Co Ltd Method for evaluating blood coagulation reaction.
NO2760138T3 (en) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US10253107B2 (en) 2012-10-26 2019-04-09 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CN104797600A (en) 2012-11-08 2015-07-22 国立大学法人宫崎大学 Antibody capable of specifically recognizing transferrin receptor
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
EP2925782B1 (en) 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
MX363407B (en) 2012-12-10 2019-03-22 Biogen Ma Inc Anti-blood dendritic cell antigen 2 antibodies and uses thereof.
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
JP2016508133A (en) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus vaccine and use thereof
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
PT2935326T (en) 2012-12-21 2020-09-14 Biogen Ma Inc Human anti-tau antibodies
CA2896091C (en) 2012-12-21 2018-06-19 Amplimmune, Inc. Anti-h7cr antibodies
CN105102618B (en) 2012-12-27 2018-04-17 中外制药株式会社 heterodimerization polypeptide
US9771413B2 (en) 2012-12-31 2017-09-26 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
JP6669500B2 (en) 2013-02-25 2020-03-18 ジェネンテック， インコーポレイテッド Methods and compositions for detecting and treating drug resistant AKT variants
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
MX370416B (en) 2013-03-13 2019-12-10 Genentech Inc Formulations with reduced oxidation.
PL2968468T3 (en) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
MY175418A (en) 2013-03-13 2020-06-24 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
JP6389236B2 (en) 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド Redox preparation
BR112015022210A8 (en) 2013-03-13 2018-01-23 Genentech Inc antibody formulations
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015023212A2 (en) 2013-03-14 2017-11-21 Gill Parkash cancer treatment using antibodies that bind to cell surface grp78
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3916103A1 (en) 2013-03-14 2021-12-01 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
BR112015023355A8 (en) 2013-03-14 2018-01-30 Abbott Lab hcv ns3 recombinant antigens and mutants thereof for enhanced antibody detection.
CA2906421C (en) 2013-03-14 2022-08-16 George J. Dawson Hcv antigen-antibody combination assay and methods and compositions for use therein
EP3216804A3 (en) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
KR102235452B1 (en) 2013-03-15 2021-04-02 제넨테크, 인크. Cell culture compositions with antioxidants and methods for polypeptide production
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
ES2753950T3 (en) 2013-03-15 2020-04-15 Amgen Res Munich Gmbh Single-chain binding molecules comprising N-terminus ABP
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
JP2016514690A (en) 2013-03-15 2016-05-23 アッヴィ バイオテクノロジー リミテッド Anti-CD25 antibodies and their use
MX2015011670A (en) 2013-03-15 2016-03-31 Biogen Ma Inc Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies.
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
RU2015144020A (en) 2013-03-15 2017-04-21 Дженентек, Инк. ENVIRONMENTS FOR CULTIVATION OF CELLS AND METHODS FOR PRODUCING ANTIBODIES
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
BR112015021341B1 (en) 2013-03-15 2023-03-28 Dana-Farber Cancer Institute Inc. ISOLATED HUMANIZED FLAVIVIRUS NEUTRALIZING MONOCLONAL ANTIBODIES AND THERAPEUTIC USES THEREOF
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
TWI679019B (en) 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2014182972A2 (en) 2013-05-10 2014-11-13 The Regents Of The University Of California Diagnostic and monitoring system for huntington's disease
CA2912526C (en) 2013-05-16 2021-09-14 Kyoto University Method for determining prognosis of cancer
JP6682426B2 (en) 2013-05-24 2020-04-15 メディミューン，エルエルシー Anti-B7-H5 antibody and use thereof
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
WO2014200018A1 (en) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
JPWO2014208482A1 (en) 2013-06-24 2017-02-23 中外製薬株式会社 A therapeutic agent for non-small cell lung cancer other than adenocarcinoma comprising humanized anti-Epiregulin antibody as an active ingredient
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6267792B2 (en) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド Methods for treating homozygous familial hypercholesterolemia
CN105518025B (en) 2013-07-03 2020-12-08 因美诺克股份公司 Human anti-IFN-alpha antibodies
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
PL3021869T3 (en) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
EP3022221B1 (en) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP3030582A4 (en) 2013-08-07 2017-05-17 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
ES2761587T3 (en) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res New screening method for the treatment of Friedreich's ataxia
JP6617239B2 (en) 2013-08-14 2019-12-11 サイドゥ サチデーブ Antibodies against Frizzled protein and methods of use thereof
PL3036320T3 (en) 2013-08-19 2021-11-02 Biogen Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2015041310A1 (en) 2013-09-20 2015-03-26 中外製薬株式会社 Treatment for hemorrhagic diseases by anti-protein-c antibody
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6534654B2 (en) 2013-10-10 2019-06-26 ベス イスラエル デアコネス メディカル センター インコーポレイティッド TM4SF1 binding protein and method of using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
JP2016536018A (en) 2013-10-28 2016-11-24 ドッツ テクノロジー コーポレイションＤＯＴＳ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． Allergen detection
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
CA3185700A1 (en) 2013-11-06 2015-05-14 Astute Medical, Inc. Assays for igfbp7 having improved performance in biological samples
CN113307873A (en) 2013-11-11 2021-08-27 中外制药株式会社 Antigen binding molecules comprising altered antibody variable regions
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP7060317B2 (en) 2013-12-04 2022-04-26 中外製薬株式会社 Antigen-binding molecule and its library whose antigen-binding ability changes according to the concentration of the compound
WO2015089073A2 (en) 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
BR112016013741A2 (en) 2013-12-17 2017-10-03 Genentech Inc USES OF PD-1 AXIS LEADING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY, AND KITS COMPRISING THEM
KR20240017102A (en) 2013-12-17 2024-02-06 제넨테크, 인크. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
WO2015099127A1 (en) 2013-12-27 2015-07-02 中外製薬株式会社 Fgfr gatekeeper mutant gene and drug targeting same
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
DK3122869T3 (en) 2014-03-24 2019-09-09 Biogen Ma Inc PROCEDURES FOR REDUCING GLUTAMINE DEPRESSION IN MAMMAL CULTURE CULTURE
JP6655548B2 (en) 2014-03-25 2020-02-26 ジェネンテック， インコーポレイテッド Methods of preparing poloxamers for use in cell culture media
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
KR20160138494A (en) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr fusions
CN106132439A (en) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US10131704B2 (en) 2014-04-25 2018-11-20 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
US20170044257A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3137910B1 (en) 2014-04-30 2019-09-25 Klinikum rechts der Isar der Technischen Universität München Diagnosis of multiple sclerosis
CN106413750B (en) 2014-05-16 2022-04-29 免疫医疗有限责任公司 Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties
KR20220151036A (en) 2014-05-27 2022-11-11 아카데미아 시니카 Anti-cd20 glycoantibodies and uses thereof
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR20230033737A (en) 2014-05-27 2023-03-08 아카데미아 시니카 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102494193B1 (en) 2014-05-28 2023-01-31 아카데미아 시니카 Anti-tnf-alpha glycoantibodies and uses thereof
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
TW201625299A (en) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
JP2017523776A (en) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド Glioblastoma diagnosis method and therapeutic composition thereof
PL3169361T3 (en) 2014-07-15 2019-11-29 Hoffmann La Roche Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
KR20240029114A (en) 2014-07-17 2024-03-05 노보 노르디스크 에이/에스 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
JP6858559B2 (en) 2014-08-20 2021-04-14 中外製薬株式会社 Method for measuring viscosity of protein solution
WO2016029079A2 (en) 2014-08-21 2016-02-25 Walter Reed Army Institute Of Research Department Of The Army Monoclonal antibodies for treatment of microbial infections
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
CN106794247B (en) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 Antibody formulations
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
AU2015326911B2 (en) 2014-09-30 2021-07-08 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
AU2015327781A1 (en) 2014-10-03 2017-04-20 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
AU2015328273B2 (en) 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
MA41685A (en) 2014-10-17 2017-08-22 Biogen Ma Inc COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
KR20230141922A (en) 2014-10-31 2023-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions and methods of stimulating and expanding t cells
EP3215166B1 (en) 2014-10-31 2024-04-24 The Trustees of the University of Pennsylvania Altering gene expression in car-t cells and uses thereof
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
AU2015342961B2 (en) 2014-11-05 2021-08-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
KR102626877B1 (en) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
RU2017119428A (en) 2014-11-06 2018-12-06 Дженентек, Инк. COMBINED THERAPY, INCLUDING THE USE OF OX40-CONNECTING AGONISTS AND TIGIT INHIBITORS
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107406503B (en) 2014-11-18 2021-07-16 詹森药业有限公司 CD47 antibodies, methods and uses
JP6788586B2 (en) 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Diagnostic method using HNL
US10517898B2 (en) 2014-11-20 2019-12-31 The Regents Of The University Of California Compositions and methods related to hematologic recovery
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN107530423B (en) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 Treatment of cancer with anti-LAP monoclonal antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2018504412A (en) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus vaccination regimen
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CA2972731A1 (en) 2015-01-24 2016-07-28 Chi-Huey Wong Cancer markers and methods of use thereof
JP2018506275A (en) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド Gene expression markers and treatment of multiple sclerosis
CN114702581A (en) 2015-01-30 2022-07-05 台湾地区“中央研究院” Universal carbohydrate compositions and methods for enhancing antibody efficacy
CA2975147A1 (en) 2015-01-31 2016-08-04 Yangbing Zhao Compositions and methods for t cell delivery of therapeutic molecules
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
TW202248212A (en) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US10988534B2 (en) 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
CN112263677A (en) 2015-02-26 2021-01-26 默克专利股份公司 PD-1/PD-L1 inhibitors for the treatment of cancer
TW202339800A (en) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Composition for treating IL-6-related diseases
CN114504652A (en) 2015-03-03 2022-05-17 科马布有限公司 Antibodies, uses and methods
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CN107223135B (en) 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) Trispecific binding molecules for the treatment of HBV infections and related disorders
AU2016233309B2 (en) 2015-03-17 2021-11-18 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
CN108368169A (en) 2015-03-18 2018-08-03 约翰霍普金斯大学 Target the new monoclonal antibody inhibitors of potassium channel KCNK9
EP3274468B1 (en) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
CN108136001B (en) 2015-04-03 2022-07-29 佐马技术有限公司 Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors
ES2899227T3 (en) 2015-04-07 2022-03-10 Alector Llc Anti-sortilin antibodies and methods of using them
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
CN107750253B (en) 2015-04-08 2022-10-04 达纳－法伯癌症研究所公司 Humanized influenza monoclonal antibodies and methods of use thereof
MX2017013348A (en) 2015-04-17 2018-08-01 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3.
EP3283099B1 (en) 2015-04-17 2022-03-02 F. Hoffmann-La Roche AG Combination therapy with coagulation factors and multispecific antibodies
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3288964B1 (en) 2015-04-27 2024-02-21 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
AU2016258742B9 (en) 2015-05-01 2023-07-13 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti CCR4 antibodies
KR20180015650A (en) 2015-05-07 2018-02-13 아게누스 인코포레이티드 Anti-OX40 antibodies and methods of use thereof
CN107592812A (en) 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 Treat the composition and method of lupus nephritis
WO2016183326A1 (en) 2015-05-12 2016-11-17 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN115043943A (en) 2015-05-15 2022-09-13 综合医院公司 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US9758539B2 (en) 2015-05-18 2017-09-12 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
CA3025145A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN107532217A (en) 2015-05-29 2018-01-02 豪夫迈·罗氏有限公司 Treatment and diagnostic method for cancer
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
DK3303394T3 (en) 2015-05-29 2020-07-06 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP3302710A4 (en) 2015-06-03 2019-02-20 The University of Queensland Mobilizing agents and uses therefor
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
CA2988982A1 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
KR20180018538A (en) 2015-06-17 2018-02-21 제넨테크, 인크. Methods for the treatment of locally advanced or metastatic breast cancer using PD-1 axis-binding antagonists and taxanes
BR112017027870A2 (en) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv antibodies and anti-sight fragments
MX2017016645A (en) 2015-06-29 2018-11-09 Genentech Inc Type ii anti-cd20 antibody for use in organ transplantation.
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
CN108289861B (en) 2015-08-03 2021-11-02 大日本住友制药肿瘤公司 Combination therapy for the treatment of cancer
TW202340452A (en) 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
EP3331562A2 (en) 2015-08-06 2018-06-13 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
MA45352A (en) 2015-08-07 2018-06-13 Univ Birmingham IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
EP3337822A1 (en) 2015-08-19 2018-06-27 Rutgers, The State University of New Jersey Novel methods of generating antibodies
BR112018001956A2 (en) 2015-08-20 2018-09-11 Hoffmann La Roche ? analyte measurement method and kit?
US10590198B2 (en) 2015-08-28 2020-03-17 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
MA48579A (en) 2015-09-01 2020-03-18 Agenus Inc ANTI-PD1 ANTIBODIES AND METHODS OF USING THEM
JP2018532990A (en) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド Glycan arrays and methods of use
PE20181336A1 (en) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd ANTIBODIES THAT BIND INTERLEUKIN 8 (IL-8) AND ITS USES
KR20200087283A (en) 2015-09-25 2020-07-20 제넨테크, 인크. Anti-tigit antibodies and methods of use
JP2018529719A (en) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Combination of PD-1 system binding antagonist and ALK inhibitor for treating ALK negative cancer
KR20180068999A (en) 2015-10-06 2018-06-22 알렉터 엘엘씨 Anti-TREM2 antibodies and methods of use thereof
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
AR106543A1 (en) 2015-11-02 2018-01-24 Netris Pharma NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Glycan-interacting compounds and methods of use
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
RS65120B1 (en) 2015-11-25 2024-02-29 Immunogen Inc Pharmaceutical formulations and methods of use thereof
CA3006596A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
AU2016365117A1 (en) 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
WO2017110980A1 (en) 2015-12-25 2017-06-29 中外製薬株式会社 Antibody having enhanced activity, and method for modifying same
AU2016381694A1 (en) 2015-12-30 2018-07-05 Genentech, Inc. Use of tryptophan derivatives for protein formulations
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
EA037027B1 (en) 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Use and method for preventing or treating gastric cancer using a composition comprising a monoclonal progastrin-binding antibody
CA3193481A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating esophageal cancer
CN114705858A (en) 2015-12-31 2022-07-05 Syncerus有限责任公司 Compositions and methods for assessing risk of cancer development
EP3397964B1 (en) 2015-12-31 2021-09-29 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating ovarian cancer
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
WO2017120536A1 (en) 2016-01-08 2017-07-13 Apg Therapeutics, Inc. Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
CN114716557A (en) 2016-02-03 2022-07-08 安进研发（慕尼黑）股份有限公司 PSMA and CD3 bispecific T cell engaging antibody constructs
MA43955B1 (en) 2016-02-03 2022-02-28 Amgen Inc Bite-format bispecific anti-bcma and anti-cd3 antibodies
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
US11262359B2 (en) 2016-02-05 2022-03-01 NanoView Biosciences, Inc. Detection of exosomes having surface markers
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
JP7023853B2 (en) 2016-03-04 2022-02-22 アレクトル エルエルシー Anti-TREM1 antibody and its usage
EP3426691A4 (en) 2016-03-07 2019-09-25 Charlestonpharma, LLC Anti-nucleolin antibodies
JP2019515876A (en) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Methods for module synthesis of N-glycans and their arrays
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
JP7034489B2 (en) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド Multispecific Fab fusion protein and its use
EP3430054B1 (en) 2016-03-15 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
MX2018011204A (en) 2016-03-15 2019-03-07 Mersana Therapeutics Inc Napi2b-targeted antibody-drug conjugates and methods of use thereof.
CN108884156B (en) 2016-03-17 2021-10-01 努玛创新有限公司 anti-TNF alpha antibodies and functional fragments thereof
EP3430042B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
SI3219726T1 (en) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-tnf alpha-antibodies and functional fragments thereof
PT3219727T (en) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anti-tnf alpha-antibodies and functional fragments thereof
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
TWI780045B (en) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
MX2018012493A (en) 2016-04-15 2019-06-06 Genentech Inc Methods for monitoring and treating cancer.
PL3443350T3 (en) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Methods for monitoring and treating cancer
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
CN109379889A (en) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 Pass through the immune activation or immunoregulatory immunotherapy for cancer via GLOBO series antigen
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2017201204A1 (en) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
MX2018014630A (en) 2016-05-27 2019-06-10 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses.
PE20190510A1 (en) 2016-06-13 2019-04-10 I Mab ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
MA45602A (en) 2016-07-08 2019-05-15 Staten Biotechnology B V ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
RU2019104896A (en) 2016-07-22 2020-08-24 Дана-Фарбер Кэнсер Инститьют, Инк. ANTIBODIES TO THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND METHODS OF THEIR USE
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
BR112019001656A2 (en) 2016-07-27 2019-05-28 Obi Pharma Inc composition, pharmaceutical composition, vaccine, method for inducing antibodies in an individual, method for treating cancer in a patient in need thereof and method for inducing or ameliorating the immune reaction in an individual in need thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN110062767B (en) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 Human antibodies, pharmaceutical compositions and methods
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
EP3496752B1 (en) 2016-08-12 2022-05-18 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
AU2017321973A1 (en) 2016-09-02 2019-03-07 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
MX2019002696A (en) 2016-09-06 2019-09-27 Dana Farber Cancer Inst Inc Methods of treating or preventing zika virus infection.
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
MX2019002946A (en) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies.
US10647767B2 (en) 2016-09-19 2020-05-12 I-Mab Biopharma Co., Ltd. Anti-GM-CSF antibodies and uses thereof
EP4360714A2 (en) 2016-09-21 2024-05-01 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
BR112019005292A2 (en) 2016-09-21 2019-09-03 Nextcure Inc siglec-15 antibodies and methods of use.
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
JP2019534251A (en) 2016-09-29 2019-11-28 ジェネンテック， インコーポレイテッド Combination therapy using MEK inhibitor, PD-1 axis inhibitor, and taxane
EP3519049A4 (en) 2016-09-30 2020-05-27 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
BR112019006710A2 (en) 2016-10-03 2019-06-25 Abbott Lab improved methods for uch-l1 status assessment in patient samples
TWI775781B (en) 2016-10-06 2022-09-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
JP2019530704A (en) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド Avelumab dosing regimen for the treatment of cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN117586403A (en) 2016-10-11 2024-02-23 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
CN110352073A (en) 2016-10-28 2019-10-18 机敏医药股份有限公司 It is used to improve the purposes of renal function for the antibody of TIMP-2
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
MA46779A (en) 2016-11-02 2019-09-11 Health Research Inc COMBINATION WITH ANTIBODY-DRUG CONJUGATES AND PARP INHIBITORS
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535299A1 (en) 2016-11-04 2019-09-11 Novimmune S.A. Anti-cd19 antibodies and methods of use thereof
EP3535294A4 (en) 2016-11-07 2020-09-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2018093841A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il-23 specific antibody
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110290800A (en) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 Conjugating biomolecules, medical composition and method
CA3082255A1 (en) 2016-11-23 2020-06-10 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
KR102533814B1 (en) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 Ligand-binding molecules capable of tunable ligand-binding activity
MA50948A (en) 2016-12-07 2020-10-14 Agenus Inc ANTIBODIES AND METHODS OF USING THE SAME
EA201991383A1 (en) 2016-12-07 2019-12-30 Эйдженус Инк. ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
SG10201914126RA (en) 2016-12-15 2020-02-27 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
CN110088130A (en) 2016-12-27 2019-08-02 豪夫迈·罗氏有限公司 New biotin monoclonal antibody specific and application thereof
KR20210123427A (en) 2016-12-27 2021-10-13 에프. 호프만-라 로슈 아게 Novel biotin-specific monoclonal antibody and use thereof
EP3562845A2 (en) 2016-12-27 2019-11-06 H. Hoffnabb-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
CN110291105B (en) 2017-01-05 2024-03-01 奈特里斯药物公司 Combination therapy of guide-1 interfering drugs and immune checkpoint inhibitor drugs
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
BR112019013238A2 (en) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES AND USES OF THE SAME
AU2018213549B2 (en) 2017-01-24 2022-02-03 I-Mab Biopharma Co., Ltd. Anti-CD73 antibodies and uses thereof
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN110234351A (en) 2017-01-30 2019-09-13 詹森生物科技公司 For treating the anti-TNF antibodies, composition and method of activity psoriatic arthritis
JP7068323B2 (en) 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー Immunoassay using at least two pegged analyte-specific binders
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
CN110418652A (en) 2017-02-07 2019-11-05 詹森生物科技公司 For treating the anti-TNF antibodies, composition and method of activity ankylosing spondylitis
CN108456251A (en) 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 Anti- PD-L1 antibody and its application
ES2953595T3 (en) 2017-03-01 2023-11-14 Hoffmann La Roche Diagnostic and therapeutic procedures for cancer
KR102653141B1 (en) 2017-03-03 2024-04-01 씨젠 인크. Glycan-interacting compounds and methods of use
TWI808963B (en) 2017-03-22 2023-07-21 法商賽諾菲公司 Treatment of lupus using humanized anti-cxcr5 antibodies
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
CN110475790A (en) 2017-03-24 2019-11-19 全药工业株式会社 Anti- IgM/B cell surface antigen bispecific antibody
KR102616819B1 (en) 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. Compositions and methods for treating lung cancer
US20200048352A1 (en) 2017-03-30 2020-02-13 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201908997UA (en) 2017-03-30 2019-10-30 Ecs Progastrin Sa Compositions and methods for detecting prostate cancer
WO2018181870A1 (en) 2017-03-31 2018-10-04 公立大学法人奈良県立医科大学 Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
EP3606554A4 (en) 2017-04-05 2020-12-09 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3609921A2 (en) 2017-04-13 2020-02-19 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
KR102637960B1 (en) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. Improved LAMP construct
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
BR112019022476A2 (en) 2017-04-28 2020-05-12 Abbott Laboratories METHODS FOR HYPERAGUDE DIAGNOSTIC AID AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING INITIAL BIOMARKERS IN AT LEAST TWO SAMPLES FROM THE SAME HUMAN
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3618854A1 (en) 2017-05-02 2020-03-11 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
CA3060856A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
US10914729B2 (en) 2017-05-22 2021-02-09 The Trustees Of Princeton University Methods for detecting protein binding sequences and tagging nucleic acids
CN110753703B (en) 2017-05-23 2024-04-09 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） Novel CD73 antibodies, their preparation and use
CA3078725A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
BR112019025313A2 (en) 2017-05-30 2020-06-23 Abbott Laboratories METHODS FOR ASSISTANCE IN DIAGNOSIS AND EVALUATION OF A LIGHT TRAUMATIC BRAIN INJURY IN A HUMAN INDIVIDUAL USING HEART TROPONIN I
JP2020522512A (en) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Method of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
JP7369038B2 (en) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
JP2020522562A (en) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
AR112336A1 (en) 2017-07-14 2019-10-16 Pfizer ANTIBODIES AGAINST MADCAM
WO2019018757A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN111491661A (en) 2017-07-27 2020-08-04 诺莫坎制药有限责任公司 M (H) DM2/4 antibodies and their use in the diagnosis and treatment of cancer
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
KR20200033798A (en) 2017-08-03 2020-03-30 알렉터 엘엘씨 Anti-CD33 antibodies and methods of use
BR112019022752A2 (en) 2017-08-03 2020-05-19 Alector Llc anti-train2 antibodies and methods of using them
AU2017428737B2 (en) 2017-08-21 2024-02-15 Adagene Inc. Dynamic human heavy chain antibody libraries
US11585014B2 (en) 2017-08-21 2023-02-21 Adagene Inc. Dynamic human antibody light chain libraries
CN111133005A (en) 2017-09-07 2020-05-08 奥古斯塔大学研究所公司 Programmed cell death protein 1 antibodies
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
EP3684801A1 (en) 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Multivalent mono- or bispecific recombinant antibodies for analytic purpose
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. Measurement of afucosylated igg fc glycans and related treatment methods
EP3700567A4 (en) 2017-10-26 2021-09-29 The Regents of The University of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP2021502066A (en) 2017-11-06 2021-01-28 ジェネンテック， インコーポレイテッド Cancer diagnosis and therapy
JP7165193B2 (en) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ Humanized antibody targeting human tissue factor
JP7266532B2 (en) 2017-11-28 2023-04-28 中外製薬株式会社 Ligand-binding molecules with tunable ligand-binding activity
DK3720879T3 (en) 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CA3083783A1 (en) 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
BR112020011627A2 (en) 2017-12-11 2020-11-17 Amgen Inc. continuous manufacturing process for bispecific antibody products
WO2019120232A1 (en) 2017-12-20 2019-06-27 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2019133902A2 (en) 2017-12-28 2019-07-04 Astute Medical, Inc. Antibodies and assays for ccl14
TW201930350A (en) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 Antibodies and variants thereof against PD-L1
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
WO2019145475A2 (en) 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR20200129125A (en) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 How to treat Crohn's disease with anti-IL23 specific antibodies
AU2019234213A1 (en) 2018-03-12 2020-09-03 Zoetis Services Llc Anti-NGF antibodies and methods thereof
AU2019235523A1 (en) 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
BR112020014591A2 (en) 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticlaudin antibodies 18.2
KR20200133376A (en) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. Antibodies to signal-regulatory protein alpha and methods of use
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
US20210048437A1 (en) 2018-03-26 2021-02-18 Glycanostiion , s.r.o. Means and methods for glycoprofiling of a protein
WO2019185040A1 (en) 2018-03-30 2019-10-03 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against lag-3 and uses thereof
AR117566A1 (en) 2018-04-02 2021-08-18 Bristol Myers Squibb Co ANTI-TREM-1 ANTIBODIES AND THEIR USES
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
SG11202010423VA (en) 2018-05-04 2020-11-27 Merck Patent Gmbh COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
KR20200122409A (en) 2018-05-10 2020-10-27 주식회사 뉴라클사이언스 Anti-family with sequence similarity 19, member A5 antibody and methods of use thereof
MA52590A (en) 2018-05-11 2021-03-17 Janssen Biotech Inc METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES
US20210261647A1 (en) 2018-05-15 2021-08-26 Immunomic Therapeutics, Inc Lamp constructs comprising allergens
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
US20210196568A1 (en) 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
MA52753A (en) 2018-05-25 2021-04-21 Alector Llc ANTI-SIRPA ANTIBODIES AND THEIR METHODS OF USE
EP3803332A1 (en) 2018-06-01 2021-04-14 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
CA3099757A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
BR112020024919A2 (en) 2018-06-08 2021-03-09 Alector Llc ANTIBODIES, NUCLEIC ACID, VECTOR, HOST CELL, METHODS OF ANTIBODY PRODUCTION AND PREVENTION, REDUCING THE RISK OR TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
EP3810653A1 (en) 2018-06-23 2021-04-28 F. Hoffmann-La Roche AG Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
KR20230065382A (en) 2018-07-13 2023-05-11 알렉터 엘엘씨 Anti-sortilin antibodies and methods of use thereof
AU2019305637A1 (en) 2018-07-18 2021-03-11 Genentech, Inc. Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
JP2021530697A (en) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド Sustained response predictor after treatment with anti-IL23 specific antibody
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista
SG11202100555PA (en) 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
TW202021616A (en) 2018-07-30 2020-06-16 美商安進公司 Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
MX2021001353A (en) 2018-08-03 2021-04-13 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3.
JP2021533149A (en) 2018-08-08 2021-12-02 ジェネンテック， インコーポレイテッド Use of tryptophan derivatives and L-methionine for protein formulations
MX2021002332A (en) 2018-08-27 2021-08-11 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct.
MA53603A (en) 2018-09-11 2021-07-21 Amgen Inc METHODS FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY MODULATION
WO2020053325A1 (en) 2018-09-12 2020-03-19 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
JP2022501332A (en) 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド How to treat and diagnose bladder cancer
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
WO2020064971A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
EP3856781A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Antibodies against soluble bcma
CN112969503A (en) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
US20210395298A1 (en) 2018-10-11 2021-12-23 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020078905A1 (en) 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
JP2022512744A (en) 2018-10-18 2022-02-07 ジェネンテック， インコーポレイテッド Diagnosis and treatment for sarcomatoid kidney cancer
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20200140533A1 (en) 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
CA3117051A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
WO2020099533A1 (en) 2018-11-16 2020-05-22 F. Hoffmann-La Roche Ag Streptavidin-coated solid phases with a member of a binding pair
MA55149A (en) 2018-11-20 2021-09-29 Janssen Biotech Inc SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
MX2021006544A (en) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer.
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
JP2022518208A (en) 2019-01-15 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Juvenile Idiopathic Arthritis
WO2020152544A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
BR112021014481A2 (en) 2019-01-23 2021-10-13 Genentech, Inc. METHOD FOR PRODUCING A MULTIMERIC POLYPEPTIDE, METHOD FOR PRODUCING A BIESPECIFIC ANTIBODY, PLURALITY OF MULTIMERIC POLYPEPTIDES, RECOMBINANT EUKARYOTIC HOST CELLS, METHOD FOR IDENTIFYING A COMBINATION OF SEQUENCES AND POLYNUCLEOTIDE KIT
US20220089770A1 (en) 2019-01-24 2022-03-24 Chugai Seiyaku Kabushiki Kaisha Novel cancer antigens and antibodies of said antigens
EP3917515A1 (en) 2019-01-29 2021-12-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
JP2022519649A (en) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド How to diagnose and treat cancer
CN113795513A (en) 2019-02-13 2021-12-14 布里格姆妇女医院 Anti-peripheral lymph node addressin antibody and use thereof
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
CA3130303A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
BR112021016923A2 (en) 2019-02-27 2021-11-03 Genentech Inc Methods for treating a patient with hematologic cancer, methods for treating a patient with relapsed or refractory mm, methods for treating a patient having a relapsed or refractory lnh, and kits
WO2020175689A1 (en) 2019-02-28 2020-09-03 学校法人順天堂 Antibody capable of binding to truncated mutant calreticulin, and diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR20210142002A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Methods of Preparation for Producing Anti-TNF Antibody Compositions
MA55283A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
CN113825765A (en) 2019-03-14 2021-12-21 詹森生物科技公司 Method for producing anti-IL 12/IL23 antibody composition
CA3199205A1 (en) 2019-03-15 2020-09-24 Cartesian Therapeutics, Inc. Anti-bcma chimeric antigen receptors
EA202192459A1 (en) 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
WO2020198413A1 (en) 2019-03-27 2020-10-01 The Trustees Of The University Of Pennsylvania Tn-muc1 chimeric antigen receptor (car) t cell therapy
CN113874392A (en) 2019-03-28 2021-12-31 丹尼斯科美国公司 Engineered antibodies
MX2021012251A (en) 2019-04-10 2021-11-12 Chugai Pharmaceutical Co Ltd Method for purifying fc region-modified antibody.
JPWO2020213665A1 (en) 2019-04-17 2020-10-22
CA3137373A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3133821A1 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
CN113939531A (en) 2019-06-03 2022-01-14 詹森生物科技公司 anti-TNF antibody compositions and methods for treating psoriatic arthritis
MX2021014882A (en) 2019-06-03 2022-03-25 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis.
KR20220017430A (en) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 Antibody Cleavage Site Binding Molecules
MX2021014644A (en) 2019-06-13 2022-04-06 Amgen Inc Automated biomass-based perfusion control in the manufacturing of biologics.
JP2022542890A (en) 2019-07-26 2022-10-07 アムジエン・インコーポレーテツド Anti-IL13 antigen binding protein
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
BR112022003740A2 (en) 2019-08-30 2022-05-31 Agenus Inc Anti-cd96 antibodies and methods of using them
US20220348650A1 (en) 2019-09-03 2022-11-03 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
KR20220057563A (en) 2019-09-04 2022-05-09 제넨테크, 인크. CD8 binders and uses thereof
WO2021050640A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
MX2022002963A (en) 2019-09-12 2022-04-06 Genentech Inc Compositions and methods of treating lupus nephritis.
CN114729045A (en) 2019-09-26 2022-07-08 斯特库比公司 Antibodies specific for glycosylated CTLA-4 and methods of use thereof
CA3151406A1 (en) 2019-09-27 2021-04-01 Raymond D. Meng Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
KR20220095205A (en) 2019-11-01 2022-07-06 아레스 트레이딩 에스.아. Combination inhibition of PD-1, TGFβ and ATM with radiotherapy for the treatment of cancer
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL292758A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
KR20220092580A (en) 2019-11-06 2022-07-01 제넨테크, 인크. Diagnosis and treatment methods for the treatment of blood cancer
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
IL293386A (en) 2019-12-05 2022-07-01 Alector Llc Methods of use of anti-trem2 antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
BR112022011228A2 (en) 2019-12-09 2022-10-11 Genentech Inc LIQUID PHARMACEUTICAL FORMULATION, ARTICLE OF MANUFACTURING, KIT AND METHOD FOR TREATMENT OF A DISEASE OR DISORDER IN AN INDIVIDUAL
MX2022007156A (en) 2019-12-12 2022-09-07 Alector Llc Methods of use of anti-cd33 antibodies.
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
KR20220136378A (en) 2020-01-31 2022-10-07 제넨테크, 인크. Method of Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines
CN113248611A (en) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 anti-BCMA antibody, pharmaceutical composition and application thereof
WO2021173565A1 (en) 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies
CN115315446A (en) 2020-03-06 2022-11-08 Go医疗股份有限公司 anti-sugar-CD 44 antibodies and uses thereof
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
US20230135752A1 (en) 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A1 (en) 2020-03-31 2023-02-08 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
JP2023520516A (en) 2020-04-03 2023-05-17 アレクトル エルエルシー Method of using anti-TREM2 antibody
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4134099A1 (en) 2020-04-06 2023-02-15 PhotoQ3 Inc. Medicine for killing tumor cells
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
JP2023106635A (en) 2020-04-17 2023-08-02 中外製薬株式会社 Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
CA3172880A1 (en) 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
JPWO2021235537A1 (en) 2020-05-22 2021-11-25
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
MX2022014902A (en) 2020-05-29 2023-01-04 Amgen Inc Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3.
EP4161653A1 (en) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2021261546A1 (en) 2020-06-24 2021-12-30 国立大学法人 東京大学 Photosensitizing dye
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
JP2023534987A (en) 2020-07-24 2023-08-15 アムジエン・インコーポレーテツド Immunogen derived from SARS-COV2 spike protein
TW202220694A (en) 2020-07-28 2022-06-01 日商中外製藥股份有限公司 Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody
TW202222832A (en) 2020-07-31 2022-06-16 美商建南德克公司 Anti-integrin beta7 antibody formulations and devices
CN116194124A (en) 2020-07-31 2023-05-30 中外制药株式会社 Pharmaceutical composition comprising cells expressing chimeric receptors
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
KR20230042301A (en) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 Improved methods and kits for detecting SARS-COV-2 proteins in samples
JP2023537022A (en) 2020-08-07 2023-08-30 バイオ－テラ ソリュ－ションズ，エルティーディー． Anti-PD-L1 antibody and its application
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN114106173A (en) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 anti-OX 40 antibodies, pharmaceutical compositions and uses thereof
CN116322763A (en) 2020-08-27 2023-06-23 学校法人顺天堂 Anti-cleavage mutant CALR-CD3 bispecific antibody and pharmaceutical composition
JP2023539279A (en) 2020-08-31 2023-09-13 ジェネンテック， インコーポレイテッド Method for producing antibodies
CN116390750A (en) 2020-09-04 2023-07-04 罗格斯新泽西州立大学 SARS-CoV-2 vaccine and antibody
US20230372484A1 (en) 2020-09-14 2023-11-23 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
US20230406909A1 (en) 2020-11-02 2023-12-21 Roche Diagnostics Operations, Inc. Sars-cov-2 nucleocapsid antibodies
CN116801906A (en) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 Combination therapy for cancer
AU2021370991A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
JP2023551113A (en) 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． Bispecific antibodies and their applications
BR112023008629A2 (en) 2020-11-06 2023-10-03 Amgen Inc POLYPEPTIDE CONSTRUCTS THAT SELECTIVELY BIND CLDN6 AND CD3
CN116323671A (en) 2020-11-06 2023-06-23 安进公司 Multi-targeting bispecific antigen binding molecules with increased selectivity
TW202233678A (en) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 Polypeptides with enhanced clipping profile
BR112023008670A2 (en) 2020-11-06 2024-02-06 Amgen Inc POLYPEPTIDE CONSTRUCTS LINKED TO CD3
EP4253415A1 (en) 2020-11-12 2023-10-04 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024512324A (en) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド Anti-glycoCD44 antibodies and their uses
CA3211581A1 (en) 2021-03-10 2022-09-15 Ellen WU Immunomodulatory molecules and uses thereof
IL305793A (en) 2021-03-12 2023-11-01 Hoffmann La Roche Pharmaceutical composition for treatment or prevention of myasthenia gravis
BR112023018353A2 (en) 2021-03-12 2024-02-06 Janssen Biotech Inc SAFE AND EFFECTIVE METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS WITH SPECIFIC ANTI-IL23 ANTIBODY
IL305836A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2022198192A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
IL305827A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4313309A1 (en) 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
JP2024513246A (en) 2021-04-09 2024-03-22 ジェネンテック， インコーポレイテッド Combination treatment with RAF inhibitor and PD-1 axis inhibitor
CA3214934A1 (en) 2021-04-12 2022-10-20 Madhavan Nallani Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
US20220372168A1 (en) 2021-05-04 2022-11-24 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
CN117279947A (en) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 Antigen binding molecules targeting CD20 and CD22 for use in proliferative diseases
US20220381796A1 (en) 2021-05-18 2022-12-01 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
CA3221411A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
EP4356129A1 (en) 2021-06-14 2024-04-24 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
CN117957251A (en) 2021-07-09 2024-04-30 詹森生物科技公司 Method for preparing anti-TNF antibody compositions
AU2022306973A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023010118A1 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
CA3229526A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
IL310861A (en) 2021-08-17 2024-04-01 Hemogenyx Pharmaceuticals Llc Bispecific anti-flt3/cd3 antibodies and methods of use
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
TW202325733A (en) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 Anti-glyco-lamp1 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023048231A1 (en) 2021-09-24 2023-03-30 株式会社PhotoQ3 Medicine for killing tumor cells
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023051663A1 (en) 2021-09-30 2023-04-06 百奥泰生物制药股份有限公司 Anti-b7-h3 antibody and application thereof
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
WO2023058705A1 (en) 2021-10-08 2023-04-13 中外製薬株式会社 Drug formulation of anti-hla-dq2.5 antibody
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
CA3237090A1 (en) 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023111168A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2023235415A1 (en) 2022-06-01 2023-12-07 Genentech, Inc. Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1991000906A1 (en) * 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAKOBOVITS A ET AL: "PRODUCTION OF ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE ENGINEERED WITH HUMAN HEAVY AND LIGHT CHAIN YACS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,US,NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, vol. 764, 29 September 1995 (1995-09-29), pages 525 - 535, XP002067728, ISSN: 0077-8923 *
See also references of WO9634096A1 *

Also Published As

Publication number Publication date
EP0823941A1 (en) 1998-02-18
WO1996034096A1 (en) 1996-10-31
CA2219486A1 (en) 1996-10-31
AU2466895A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
EP0823941A4 (en) Human antibodies derived from immunized xenomice
IL136335A0 (en) Monoclonal human natural antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
IL128406A0 (en) Monoclonal antibodies
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
HK1015282A1 (en) High affinity human monoclonal antibodies specificfor rsv f-protein.
AU1462300A (en) Human pan-hcv human monoclonal antibodies
ZA979599B (en) Humanized anti-CD11a antibodies
AU5365296A (en) Human monoclonal antibody against lung carcinoma
AP2001002213A0 (en) Human monoclonal antibodies to ctla-4
IL130864A0 (en) Monoclonal antibodies to human cd6
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
EP0809806A4 (en) Monoclonal antibodies for human osteogenic cell surface antigens
ZA962280B (en) RAGE tumor rejection antigens
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
HUP9800613A3 (en) Humanized antibody against human fas-antigene
EP0977590A4 (en) Human monoclonal antibodies
AU5021796A (en) Recombinant human anti-lewis b antibodies
HUP9601394A1 (en) Two-function brassiere
IL102088A0 (en) Me20:monoclonal antibodies and antigen for human melanoma
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
GB9718911D0 (en) Monoclonal antibodies
AU1809695A (en) Tumor associated monoclonal antibody 123av16
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/00 A, 7C 07K 16/00 B

17Q First examination report despatched

Effective date: 20020205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030308

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009153

Country of ref document: HK